Alkermes plc - Ordinary Shares (ALKS) News

Alkermes plc - Ordinary Shares (ALKS)

Today's Latest Price: $22.19 USD

0.72 (3.35%)

Updated Jan 22 4:00pm

Add ALKS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

StocksNews Articles for ALKS

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ALKS News From Around the Web

Below are the latest news stories about Alkermes plc that investors may wish to consider to help them evaluate ALKS as an investment opportunity.

Bristol Myers' (BMY) Opdivo Label Expansion Gets Priority Review

Bristol Myers' (BMY) sBLA for the label expansion of Opdivo for gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma gets priority review.

Yahoo | January 21, 2021

Novo Nordisk (NVO) Files for Ozempic's Label Expansion in US

Novo Nordisk (NVO) submits a label expansion application to the FDA for the existing marketing authorization for Ozempic to include a new dose of 2.0 mg.

Yahoo | January 21, 2021

AstraZeneca's (AZN) Enhertu Gets EU Nod for Breast Cancer

AstraZeneca's (AZN) Enhertu gets EU approval for metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens.

Yahoo | January 21, 2021

Addiction Treatment Market Size, Top Key Players, Latest Trends, Regional Insights and Global Industry Dynamics By 2027 | Alkermes , Allergan, Cipla, GSK, Pfizer

When a person is addicted to a drug and if the person fails to control the urge, they are given addiction control treatment. This condition is concerned with illegal drugs, nicotine, painkillers, and alcohol. Usage of drugs regularly affects the

OpenPR | January 18, 2021

Novartis' (NVS) Ligelizumab Gets Breakthrough Therapy Status

Novartis (NVS) gets Breakthrough Therapy designation by the FDA for ligelizumab for the treatment of chronic spontaneous urticaria.

Yahoo | January 15, 2021

The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) AbbVie Inc (NYSE: ABBV ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alkermes Plc (NASDAQ: ALKS ) AtriCure Inc. (NASDAQ: ATRC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) BIOLASE Inc (NASDAQ: BIOL ) (announced an agreement to expand laser adoption and hands-on training programs in targeted geographies) CareDx Inc (NASDAQ: CDNA ) Celsius Holdings, Inc. (NASDAQ: CELH ) DermTech Inc (NASDAQ: DMTK ) Dyne Therapeutics Inc (NASDAQ: DYN ) Edap Tms SA (NASDAQ: EDAP ) Evelo Biosciences Inc (NASDAQ: EVLO ) EXACT Sciences Corporation (NASDAQ: EXAS ) Eyenovia Inc (NASDAQ: EYEN ) Genetron Holdings Ltd – ADR (NASDAQ...

Benzinga | January 13, 2021

Regeneron (REGN), U.S. Government Ink Deal for COVID-19 Treatment

Regeneron (REGN) inks deal with the U.S. government to sell additional 1.25 million doses (an agreement value of up to $2.625 billion) of its COVID-19 antibody cocktail.

Yahoo | January 13, 2021

Horizon (HZNP) Provides Preliminary 2020 Financial Results

Horizon (HZNP) provides 2020 preliminary financial results and updates on its key drugs.

Yahoo | January 12, 2021

Ultragenyx (RARE) Presents Preliminary 2020 Revenues & Guidance

Ultragenyx (RARE) provides preliminary 2020 Crysvita revenues and 2021 revenue guidance for the same.

Yahoo | January 12, 2021

NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session

NuCana (NCNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Yahoo | January 11, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5888 seconds.